Comparative immune profiling of acute respiratory distress syndrome patients with or without SARS-CoV2 infection

M Roussel; J Ferrant; F Reizine; S Le Gallou; J Dulong; S Carl; M Lesouhaitier; M Gregoire; N Bescher; C Verdy; M Latour; I Bézier; M Cornic; A Vinit; C Monvoisin; B Sawitzki; S Leonard; S Paul; J Feuillard; R Jeannet; T Daix; Vijay K. Tiwari; J M Tadié; M Cogné; K Tarte

doi:10.1016/j.xcrm.2021.100291

Comparative immune profiling of acute respiratory distress syndrome patients with or without SARS-CoV2 infection

M Roussel, J Ferrant, F Reizine, S Le Gallou, J Dulong, S Carl, M Lesouhaitier, M Gregoire, N Bescher, C Verdy, M Latour, I Bézier, M Cornic, A Vinit, C Monvoisin, B Sawitzki, S Leonard, S Paul, J Feuillard, R JeannetT Daix, Vijay K. Tiwari, J M Tadié, M Cogné, K Tarte

Wellcome Wolfson Institute for Experimental Medicine

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

95 Downloads (Pure)

Abstract

Acute respiratory distress syndrome (ARDS) is the main complication of COVID-19, requiring admission to Intensive Care Unit (ICU). Despite extensive immune profiling of COVID-19 patients, to what extent COVID-19-associated ARDS differs from other causes of ARDS remains unknown. To address this question, we build 3 cohorts of patients categorize in COVID-19 ARDS , COVID-19 ARDS , and COVID-19 ARDS , and compare their immune landscape analyze by high-dimensional mass cytometry on peripheral blood. A cell signature associating S100A9/calprotectin-producing CD169 monocytes, plasmablasts, and Th1 cells is found in COVID-19 ARDS , unlike COVID-19 ARDS patients. Moreover, this signature is essentially share with COVID-19 ARDS patients, suggesting that severe COVID-19 patients, whatever they experience or not ARDS, display similar immune profiles. We show an increase in CD14 HLA-DR and CD14 CD16 monocytes correlate to the occurrence of adverse events during ICU stay. We demonstrate that COVID-19-associated ARDS display a specific immune profile, and might benefit from personalize therapy in addition to standard ARDS management.

Original language	English
Article number	100291
Number of pages	18
Journal	Cell Reports Medicine
Volume	2
Early online date	06 May 2021
DOIs	https://doi.org/10.1016/j.xcrm.2021.100291
Publication status	Published - 15 Jun 2021

Access to Document

10.1016/j.xcrm.2021.100291Licence: CC BY-NC-ND

Comparative immune profiling of acute respiratory distress syndrome patients with or without SARS-CoV-2 infection
Copyright 2021 the authors. This is an open access article published under a Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits distribution and reproduction for non-commercial purposes, provided the author and source are cited.
Final published version, 5.21 MBLicence: CC BY-NC-ND

Cite this

Roussel, M., Ferrant, J., Reizine, F., Le Gallou, S., Dulong, J., Carl, S., Lesouhaitier, M., Gregoire, M., Bescher, N., Verdy, C., Latour, M., Bézier, I., Cornic, M., Vinit, A., Monvoisin, C., Sawitzki, B., Leonard, S., Paul, S., Feuillard, J., ... Tarte, K. (2021). Comparative immune profiling of acute respiratory distress syndrome patients with or without SARS-CoV2 infection. Cell Reports Medicine, 2, [100291]. https://doi.org/10.1016/j.xcrm.2021.100291

@article{1c75355b98ce4782a4061b97f7e301c5,

title = "Comparative immune profiling of acute respiratory distress syndrome patients with or without SARS-CoV2 infection",

abstract = "Acute respiratory distress syndrome (ARDS) is the main complication of COVID-19, requiring admission to Intensive Care Unit (ICU). Despite extensive immune profiling of COVID-19 patients, to what extent COVID-19-associated ARDS differs from other causes of ARDS remains unknown. To address this question, we build 3 cohorts of patients categorize in COVID-19 ARDS , COVID-19 ARDS , and COVID-19 ARDS , and compare their immune landscape analyze by high-dimensional mass cytometry on peripheral blood. A cell signature associating S100A9/calprotectin-producing CD169 monocytes, plasmablasts, and Th1 cells is found in COVID-19 ARDS , unlike COVID-19 ARDS patients. Moreover, this signature is essentially share with COVID-19 ARDS patients, suggesting that severe COVID-19 patients, whatever they experience or not ARDS, display similar immune profiles. We show an increase in CD14 HLA-DR and CD14 CD16 monocytes correlate to the occurrence of adverse events during ICU stay. We demonstrate that COVID-19-associated ARDS display a specific immune profile, and might benefit from personalize therapy in addition to standard ARDS management. ",

author = "M Roussel and J Ferrant and F Reizine and {Le Gallou}, S and J Dulong and S Carl and M Lesouhaitier and M Gregoire and N Bescher and C Verdy and M Latour and I B{\'e}zier and M Cornic and A Vinit and C Monvoisin and B Sawitzki and S Leonard and S Paul and J Feuillard and R Jeannet and T Daix and Tiwari, {Vijay K.} and Tadi{\'e}, {J M} and M Cogn{\'e} and K Tarte",

year = "2021",

month = jun,

day = "15",

doi = "10.1016/j.xcrm.2021.100291",

language = "English",

volume = "2",

journal = "Cell Reports Medicine",

issn = "2666-3791",

publisher = "Cell Press",

}

Roussel, M, Ferrant, J, Reizine, F, Le Gallou, S, Dulong, J, Carl, S, Lesouhaitier, M, Gregoire, M, Bescher, N, Verdy, C, Latour, M, Bézier, I, Cornic, M, Vinit, A, Monvoisin, C, Sawitzki, B, Leonard, S, Paul, S, Feuillard, J, Jeannet, R, Daix, T, Tiwari, VK, Tadié, JM, Cogné, M & Tarte, K 2021, 'Comparative immune profiling of acute respiratory distress syndrome patients with or without SARS-CoV2 infection', Cell Reports Medicine, vol. 2, 100291. https://doi.org/10.1016/j.xcrm.2021.100291

TY - JOUR

T1 - Comparative immune profiling of acute respiratory distress syndrome patients with or without SARS-CoV2 infection

AU - Roussel, M

AU - Ferrant, J

AU - Reizine, F

AU - Le Gallou, S

AU - Dulong, J

AU - Carl, S

AU - Lesouhaitier, M

AU - Gregoire, M

AU - Bescher, N

AU - Verdy, C

AU - Latour, M

AU - Bézier, I

AU - Cornic, M

AU - Vinit, A

AU - Monvoisin, C

AU - Sawitzki, B

AU - Leonard, S

AU - Paul, S

AU - Feuillard, J

AU - Jeannet, R

AU - Daix, T

AU - Tiwari, Vijay K.

AU - Tadié, J M

AU - Cogné, M

AU - Tarte, K

PY - 2021/6/15

Y1 - 2021/6/15

N2 - Acute respiratory distress syndrome (ARDS) is the main complication of COVID-19, requiring admission to Intensive Care Unit (ICU). Despite extensive immune profiling of COVID-19 patients, to what extent COVID-19-associated ARDS differs from other causes of ARDS remains unknown. To address this question, we build 3 cohorts of patients categorize in COVID-19 ARDS , COVID-19 ARDS , and COVID-19 ARDS , and compare their immune landscape analyze by high-dimensional mass cytometry on peripheral blood. A cell signature associating S100A9/calprotectin-producing CD169 monocytes, plasmablasts, and Th1 cells is found in COVID-19 ARDS , unlike COVID-19 ARDS patients. Moreover, this signature is essentially share with COVID-19 ARDS patients, suggesting that severe COVID-19 patients, whatever they experience or not ARDS, display similar immune profiles. We show an increase in CD14 HLA-DR and CD14 CD16 monocytes correlate to the occurrence of adverse events during ICU stay. We demonstrate that COVID-19-associated ARDS display a specific immune profile, and might benefit from personalize therapy in addition to standard ARDS management.

AB - Acute respiratory distress syndrome (ARDS) is the main complication of COVID-19, requiring admission to Intensive Care Unit (ICU). Despite extensive immune profiling of COVID-19 patients, to what extent COVID-19-associated ARDS differs from other causes of ARDS remains unknown. To address this question, we build 3 cohorts of patients categorize in COVID-19 ARDS , COVID-19 ARDS , and COVID-19 ARDS , and compare their immune landscape analyze by high-dimensional mass cytometry on peripheral blood. A cell signature associating S100A9/calprotectin-producing CD169 monocytes, plasmablasts, and Th1 cells is found in COVID-19 ARDS , unlike COVID-19 ARDS patients. Moreover, this signature is essentially share with COVID-19 ARDS patients, suggesting that severe COVID-19 patients, whatever they experience or not ARDS, display similar immune profiles. We show an increase in CD14 HLA-DR and CD14 CD16 monocytes correlate to the occurrence of adverse events during ICU stay. We demonstrate that COVID-19-associated ARDS display a specific immune profile, and might benefit from personalize therapy in addition to standard ARDS management.

U2 - 10.1016/j.xcrm.2021.100291

DO - 10.1016/j.xcrm.2021.100291

M3 - Article

C2 - 33977279

VL - 2

JO - Cell Reports Medicine

JF - Cell Reports Medicine

SN - 2666-3791

M1 - 100291

ER -

Comparative immune profiling of acute respiratory distress syndrome patients with or without SARS-CoV2 infection

Abstract

Access to Document

Fingerprint

Cite this